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Summary: Twenty-five patients with different stages of liver cirrhosis were evaluated with regard to the degree
of liver synthesis reduction, the extent of the decrease of blood coagulation factors and/or alterations of the
fibrinolytic system. For the assessment of the residual level of liver synthesis we used pseudo-cholinesterase
and serum albumin as references. We did not find a correlation between these quantities and antithrombin
III or fibrinogen, but highly significant inverse correlations with tissue plaminogen activator activity and D-
dimer concentration. We found considerable alterations in the concentrations of the coagulation and fibri-
nolysis factors, with the exception of fibrinogen and plasminogen activator inhibitor. Significant increases
were seen for thrombin-antithrombin III complex, tissue plasminogen activator activity and D-dimer, while
significant decreases were seen for antithrombin III and oc2-antiplasmin, compared with a group of healthy
volunteers. In the group of patients with liver cirrhosis and reduced liver synthesis, as documented by lowered
pseudo-cholinesterase and serum albumin, the reduction of both antithrombin III and oc2-antiplasmin was
most prominent. Intravascular coagulation was negligibly small. For the fibrinolytic system, the increase of
tissue plasminogen activator, the decrease of the flbrinolysis inhibitor (a2-antiplasmin) and the elevated D-
dimer concentration seem to be important. These results suggest an acceleration of flbrinolysis and the
prolonged presence of cross-linked fibrin degradation products.
Introduction . , . , , , , .
consumption of blood coagulation factors plays a role
The liver plays a central role in the mechanisms of in liver cirrhosis (2, 3). The impaired synthesis of the
blood coagulation and flbrinolysis. It is well known coagulation factors and the possible presence of dif-
that patients with chronic liver disease may have fuse intravascular coagulation hamper the correct
severe coagulopathies. Most blood coagulation and asessement of the fibrinolytic activity. But liver cir-
profibrinolytic proteins, like antithrombin III, plas- rhosis is probably the most common clinical condition
minogen and a2-antiplasmin are synthesized in the in which an increase of products of endogenous fi-
liver. Impairment of the liver function has repercus- brinolytic activity can be measured (4, 5).
sions on the synthesis of these and other proteins (1). _ . „ , .The aim of this study was to estimate the extent of
Besides the reduction of coagulation and flbrinolysis the decrease of antithrombin III, due to decreased
factors, the synthesis of other proteins is also de- liver synthesis, and the proportion of this decrease
creased. In this respect, pseudo-cholinesterase (EC caused by enhanced consumption. Activation of the
3.1.1.8) and serum albumin are known to be reliable clotting pathway was determined by measurement of
indicators of the reduced protein synthesis by the liver, the thrombin-antithrombin III complex. Fibrinogen
There has been much debate as to whether and to was determined as an additional measure of possible
what extent, in addition to synthesis reduction, the consumptive coagulation.
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In addition, we assessed the flbrinolysis regulating
constituents, a2-antiplasmin, tissue plasminogen acti-
vator and plasminogen activator inhibitor-1, as well
as the fibrinolysis-derived D-dimers, in order to assess
the coagulation/fibrinolysis balance.
The relevant part of the coagulation and flbrinolysis
cascade is given in figure 1.
Materials and Methods
Patients selection
Twenty-five patients (18 males and 7 females aged from 38 to
82 years) at different stages of hepatic failure were studied.
Patients were considered to have cirrhosis if they showed either
biopsy evidence of cirrhosis or documented portal hypertension
(presence of oesophagus varices or redistribution of tracer to
spleen and bone marrow on liver-spleen scanning) in the setting
of clear-cut parenchymal liver disease and appropriate historical
background (heavy alcohol abuse or viral hepatitis).
Most patients had alcoholic liver disease, while the remainder
had either post-viral cirrhosis or cirrhosis of unknown origin.
The severity of liver disease was estimated using the Child-
Turcotte classification (6). Seven patients had mild cirrhosis
(Child A), eleven had moderate cirrhosis (Child B) and seven
had advanced cirrhosis (Child C). Exclusion criteria were a
coexistent malignancy, thromboembolic process or medication
known to have influence on the coagulation system.
The control group consisted of fifty subjectively healthy vol-
unteers.
Methods
The pseudo-cholinesterase activity was measured in serum (ref-
erence range 2800-9000 U/l) with butyrylthiocholine iodide as
substrate according to the manufacturer's instructions (Boeh-
ringer Mannheim, Germany).
Fibrinogen was determined according to Clauss on a Schnittger
and Gross coagulometer, with reagents from HofTmann-La
Roche. The chromogenic substrate assay for antithrombin III
was from Kabi Vitrum. Thrombin-antithrombin III was deter-
mined with an Elisa kit from the Behring Corporation (Mar-
burg, Germany).
D-Dimer was assayed in plasma with an Elisa method (Boeh-
ringer Mannheim Corp., Mannheim, Germany). For the deter-
mination of plasminogen activator inhibitor-1, the test kit of
Kabi Vitrum Diagnostica (Mölndal, Sweden) Coa-set PAI was
used. The a2-antiplasmin and tissue-plasminogen activator ac-
tivity tests were also from Kabi Vitrum Diagnostica.
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Fig. 1. Relevant part of the coagulation and fibrinolysis cascade
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Samples
Blood for the plasma determinations was collected by veni-
puncture with sodium citrate as anticoagulant (final concentra-
tion 11 mmol/1). Plasma was prepared by centrifugation at
1800 g for 30 min. The plasma was stored at -70 °C in plastic
tubes and thawed with tap water for 5 min before serial analysis.
For the measurement of tissue plasminogen activator activity,
1 ml of citrate blood was added to a separate tube containing
0.5 ml acetate buffer (pH = 3.9). The tube was centrifuged
immediately (30 min, 1800g) and the plasma separated. The
collected plasma was acidified with 20% acetic acid (final pH
of the plasma sample 4.0—4.1). This plasma was stored at
— 70 °C in plastic tubes and thawed with tap water for 5 min
before analysis.
For the serum determinations the venous blood was collected
in plain plastic vials (Sarstedt, Nümbrecht, Germany). The
blood was allowed to clot at room temperature for 60 min,
then centrifuged in the collection tube (15 min, 3000g). The
serum was stored at — 70 °C until analysis.
Sta t is t ical analysis
For statistical analysis, the Mann- Whitney- Wilcoxon and Spear-
man rank correlation tests were used, and a p-value of < 0.05
was considered to be significant. All values were expressed as
mean ± SD.
Results
We did not find a significant correlation between
pseudo-cholinesterase and antithrombin III
(r = 0.2241; p = 0.2722) or between serum albumin
and antithrombin III (r = 0.3050, p = 0.1357). How-
ever a significant correlation between pseudo-cholin-
esterase and serum albumin existed (r = 0.6888,
p = 0.007). For pseudo-cholinesterase and serum al-
bumin, highly significant inverse correlations were
found with D-dimer and tissue plasminogen activator
activity (tab. 1).
Comparison of the patient group with a reference
group with respect to coagulation and fibrinolysis
factors is summarized in table 2. With the exception
Tab. 1. Relevant Spearman rank correlations between pseudo-
cholinesterase and serum albumin on one hand and
antithrombin III, D-dimer and tissue plasminogen ac-
tivator on the other hand.
Spearman rank correlation between: p-value
Antithrombin-III and pseudo-cholin- 0.2241 0.2722
esterase
Antithrombin-III and serum albumin 0.3050 0.1357
Pseudo-cholinesterase and serum al- 0.6888 0.0007
bumin
D-dimer and pseudo-cholinesterase -0.6373 0.0035
D-dimer and serum albumin —0.6255 0.0041
Tissue plasminogen activator and —0.4360 0.0327
pseudo-cholinesterase
Tissue plasminogen activator and —0.4970 0.0149
serum albumin
Tab. 2. Comparison of the patient group and the reference group: the percentages of values exceeding the upper or lower limit
of the reference ranges are given. The differences of the mean values were tested with the Mann-Whitney-Wilcoxon test.
Blood constituents
Fibrinogen(g/i)
Antithrombin III*
Thrombin-antithrombin III*
Gig/1)
D-dimer*
a2-antiplasmin*
Tissue plasminogen activator*
(x 103IU/1)
Plasminogen activator inhibitor- 1
(x 103AU/1)
Pseudo-cholinesterase*
(IU/1)
Albumin*
(g/1)
Reference
(n = 50)
mean
2.9
98.4
2.5
238
98.0
1.6
2.2
5900
42.5
group
SD
0.6
12.2
0.9
100
11.0
0.5
1.2
1500
3.8
Patient group
(n = 25)
mean
3.2
61.0
5.1
2492
64.9
4.0
1.8
3148
30.0
SD
3.4
15.9
3.5
2713
17.8
2.9
2.0
1750
10.0
Decreased
values
0
85
4
0
76
13
0
42.9
65.2
Raised
values
44
0
48
72
0
73
9
0
0
Signifi-
cancy
p-value
n. s.
< 0.0001
< 0.001
< 0.0001
< 0.0001
<0.02
n. s.
< 0.0001
< 0.0001
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of fibrinogen and plasminogen activator inhibitor-1,
we found significant differences between the mean
values of the patient and the reference group for all
other quantities. The mean of antithrombin-III was
reduced from 98.4% (= 300 mg/1) to 61.6% (=186
mg/1), for pseudo-cholinesterase from 5900 U/l (mean
value of the reference group) to 3148 U/l and for
serum albumin from 42.5 to 30.0 g/1. With regard to
the fibrinolysis quantities we found a significant de-
crease of a2-antiplasmin from 98% to 64.9%, a sig-
nificant increase for D-dimer (from 238 to 2482 mg/1)
and tissue plasminogen activator activity (from 1.6 to
4.0 · 103 AU/1).
Discussion
In the present study, some specific coagulation factors
(antithrombin III, thrombin-antithrombin III com-
plex, fibrinogen) and a number of factors of the
fibrinolytic system (a2-antiplasmin, tissue plasmino-
gen activator activity, plasminogen activator inhibi-
tor-1 and D-dimer) were determined in the blood of
liver cirrhosis patients. Correlations were sought be-
tween the changes in the concentrations of these fac-
tors and the extent of decreased liver synthesis, as
indicated by the catalytic concentration of pseudo-
cholinesterase and the concentration of serum albu-
min. The activity of pseudo-cholinesterase was de-
creased to 53.4% of the mean reference pool serum
activity, whereas serum albumin decreased by 29.5%.
The antithrombin III level decreased from 98.5% to
61.0% (a reduction of 37.5%). Although these figures
are in concordance with each other, we only could
demonstrate a significant correlation between pseudo-
cholinesterase and serum albumin (r = 0.6888;
p = 0.0007), with no significant correlation between
antithrombin III and pseudo-cholinesterase or serum
albumin. This implies either a separate location for
the antithrombin III synthesis in the liver, or, as often
stated in liver cirrhosis, an enhanced consumption of
antithrombin III. Several authors (7, 8) have studied
this factor of intravascular clotting activation by
measuring fibrinopeptide A. The results were however
conflicting and gave no clear evidence for blood co-
agulation consumption. The results of this study how-
ever almost exclude diffuse intravascular coagulation,
because the antithrombin HI level reduction of 37.5%
equals a reduction of approximately 112.5 mg/1,
whereas the coagulation marker, thrombin-anti-
thrombin III complex, showed only a limited increase
(from 2.5 in the reference group to 5.1 g/1 in the
patient group). Thus, coagulation activation is present
but the proportion seems to be negligible. This view
is supported by the unaltered fibrinogen level in these
patients.
With regard to fibrinolysis, we found an enhanced
tissue plasminogen activator activity in the cirrhosis
group in comparison with a reference group of healthy
volunteers, which is in agreement with earlier studies
on this topic (9, 10). Furthermore we found un-
changed levels of plasminogen activator inhibitor-1
activity and increased concentrations of fibrin de-
gradation products (D-dimers). This raises the ques-
tion of whether hyperfibrinolysis can really be as-
sumed when fibrin degradation products are en-
hanced, but there is no substantial evidence for co-
agulation activation, as in the present study. The
explanation might be that the synthesis of oc2-anti-
plasmin is reduced (10) and the clearance of tissue
plasminogen activator in patients with liver cirrhosis
is diminished (11, 12). Reduction of the excretion of
tissue plasminogen activator leads to enhanced levels
of tissue plasminogen activator; this in turn stimulates
the generation of plasmin, which is inadequately in-
hibited by the decreased a2-antiplasmin. The resulting
effect might be a continuous production of cross-
linked fibrin degradation products (D-dimers), which
leads, in combination with a reduced clearance, to
enhanced D-dimer levels. Indeed, enhanced tissue
plasminogen activator activity levels, strongly ele-
vated D-dimer levels and decreased a2-antiplasmin
concentrations have been found in this study. More-
over, plasma urokinase-type plasminogen activator
may be elevated in some subjects with liver cirrhosis
(13), and this also contributes to an enhancement of
fibrinolysis.
Recently Leebeek et al. (14) showed that the ratios of
tissue plasminogen activator antigen and plasminogen
activator inhibitor-1 antigen were increased in most
patients with liver cirrhosis. They discuss the possi-
bility that it may be caused by a selective increase in
tissue plasminogen activator synthesis or by a selective
change in the clearance, by the diseased liver, of tissue
plasminogen activator versus plasminogen activator
inhibitor-1. The overall effect is a shift of the balance
between tissue plasminogen activator and plasmino-
gen activator inhibitor-1.
In summary our results show that the antithrombin
HI reduction is much more prominent than the throm-
bin-antithrombin III complex elevation. Thus, only a
minor proportion of antithrombin III reduction ap-
pears to be due to consumption. The level of tissue
plasminogen activator is sufficient to activate plas-
minogen to plasmin, which is not adequately inhibited
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by a2-antiplasmin and therefore leads to enhanced
fibrinolysis (D-dimers). The relatively high D-dimer
concentrations present in the plasma of cirrhosis pa-
tients are probably due to impaired clearance by the
liver. In this manner, a kind of hyperfibrinolysis is
mimicked, which can interfere with the coagulation
process and cause or aggravate bleeding complica-
tions in patients with cirrhosis of the liver (15).
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